



TFW

DOCKET NO.: CELL-0310/PAC019-Usw01

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

David Alan Owen, et al.

Confirmation No.: 4658

Application No.: 10/560,327

Group Art Unit: 1625

Filing Date: May 23, 2006

Examiner: Not Yet Assigned

For: HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS

DATE OF DEPOSIT: *October 31, 2006*

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450

Elizabeth A. McLoud

TYPED NAME: Elizabeth A. McLoud

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☒ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- ☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

- ☒ Copies of reference numbers **1 - 14** listed on the attached Form PTO-1449 are enclosed herewith.

- ☐ Copies of reference numbers - on the attached Form PTO 1449 are not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).

- ☐ Copies of references - are not being submitted because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application number , filed for

which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.

- ☐ The relevance of those listed references which are not in the English language is as follows:

There are no listed references which are not in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date: *October 31, 2006*

Jane E. Inglese
Jane E. Inglese
Registration No. 48,444

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439




Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. CELL-0310/PAC019-Usw01	Application No. 10/560,327
	Applicant David Alan Owen, et al.	
	Filing Date May 23, 2006	Group 1625
	Confirmation No. 4658	

NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	1	Bonnefoy, J., et al., "Functions of CD23," <i>Int. Rev. Immunol.</i> , 1997 , <i>16</i> , 113-128
	2	Chomarat, P., et al., "Increased production of soluble CD23 in rheumatoid arthritis, and its regulation by interleukin-4," <i>Arthritis & Rheumatism</i> , 1993 , <i>36</i> (2), 234-242
	3	Christie, G., et al., "IgE secretion is attenuated by an inhibitor of proteolytic processing of CD23 (FcεRII)," <i>Eur. J. Immunol.</i> , 1997 , <i>27</i> , 3228-3235
	4	Mayer, R.J., et al., "CD23 shedding: requirements for substrate recognition and inhibition by dipeptide hydroxamic acids," <i>Inflammation Research</i> , 2002 , <i>51</i> , 85-90
	5	Marolewski, A., et al., "CD23 (FcεRII) release from cell membranes is mediated by a membrane-bound metalloprotease," <i>Biochem. J.</i> , 1998 , <i>333</i> , 573-579
	6	Morré, D.J., et al., "Cell Membrane Techniques – Part II; Preparation of mammalian plasma membranes by aqueous two-phase partition," <i>Bio Techniques</i> , 1989 , <i>7</i> (9), 946-949, 951-954, 956-958
	7	Sarfati, M., et al., "Expression, regulation and function of human FcεRII (CD23) antigen," <i>Immunol. Res.</i> , 1992 , <i>11</i> , 260-272
	8	Sutton, B.J., et al., "The human IgE network," <i>Nature</i> , 1993 , <i>366</i> , 421-428
	9	Tsicopoulos, A., et al., "The role of CD23 in allergic disease," <i>Clin. & Exp. Allergy</i> , 2000 , <i>30</i> , 602-605

EXAMINER	DATE CONSIDERED
----------	-----------------



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. CELL-0310/PAC019-Usw01	Application No. 10/560,327
	Applicant David Alan Owen, et al.	
	Filing Date May 23, 2006	Group 1625
	Confirmation No. 4658	

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
	10	WO 98/05635 A1	02/12/98	PCT		
	11	WO 99/24399 A1	05/20/99	PCT		
	12	WO 00/12477 A1	03/09/00	PCT		
	13	WO 01/62715 A1	08/30/01	PCT		
	14	WO 01/85721 A1	11/15/01	PCT		

EXAMINER	DATE CONSIDERED
-----------------	------------------------